Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to be a major transfusion-transmitted pathogen; however, convalescent plasma is a treatment option used in some regions. The risk of transfusion-transmitted infections can be minimized by implementing Pathogen Inactivation (PI), such as THERAFLEX MB-plasma and THERAFLEX UV-Platelets systems. Here we examined the capability of these PI systems to inactivate SARS-CoV-2. Study Design and MethodsSARS-CoV-2 spiked plasma units were treated using the THERAFLEX MB-Plasma system in the presence of methylene blue (similar to 0.8 mu mol/L; visible light doses: 20, 40, 60, and 120 [standard] J/cm(2)). SARS-CoV-2 spiked platelet concentrates (PCs) were treated using the THERAFLEX UV-platelets system (UVC doses: 0.05, 0.10, 0.15, and 0.20 [standard] J/cm(2)). Samples were taken prior to the first and after each illumination dose, and viral infectivity was assessed using an immunoplaque assay. ResultsTreatment of spiked plasma with the THERAFLEX MB-Plasma system resulted in an average >= 5.03 log(10) reduction in SARS-CoV-2 infectivity at one third (40 J/cm(2)) of the standard visible light dose. For the platelet concentrates (PCs), treatment with the THERAFLEX UV-Platelets system resulted in an average >= 5.18 log(10) reduction in SARS-CoV-2 infectivity at the standard UVC dose (0.2 J/cm(2)). ConclusionsSARS-CoV-2 infectivity was reduced in plasma and platelets following treatment with the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets systems, to the limit of detection, respectively. These PI technologies could therefore be an effective option to reduce the risk of transfusion-transmitted emerging pathogens.

Automated summary

The THERAFLEX MB-Plasma and THERAFLEX UV-Platelets systems were found to effectively reduce the infectivity of SARS-CoV-2 in plasma and platelets, respectively.